Acalabrutinib (7) – Calquence®
Chronic lymphocytic leukaemia, first-line treatment, in combination with venetoclax and obinutuzumab
Characteristics
| Start date | 01.07.2025 – Marketing authorisation: 02.06.2025 |
|---|---|
| Resolution | 18.12.2025 |
| INN | Acalabrutinib |
| Brand name | Calquence® |
| Pharm. company | AstraZeneca GmbH |
| G-BA Procedure ID | D-1228 |
| ATC code | L01EL02 BTK inhibitors (L01EL) |
| ICD-10 codes (AIS) | C91.10Chronic lymphocytic leukemia of B-cell type with failed remission, C91.11Chronic lymphocytic leukemia of B-cell type in remission |
| Alpha-ID codes (AIS) | I25521CLL (chronic lymphocytic leukemia), I31079CLL (chronic lymphocytic leukemia) in complete remission |
| Therapeutic area | Oncological diseases |
| Reason for procedure | New therapeutic indication |
| Therapeutic indication of the resolution |
|---|
|
Calquence, in combination with venetoclax and obinutuzumab, is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). |
| Subpopulation | Indication | Comparator |
|---|---|---|
| Erwachsene mit nicht vorbehandelter chronischer lymphatischer Leukämie (CLL) |
Studies and Results
- Clinical trials
- The AMPLIFY trial is an open-label, multicentre, randomised, controlled Phase III trial that has been ongoing since February 2019, in which acalabrutinib + venetoclax (AV) or acalabrutinib + venetoclax + obinutuzumab (AVO) were compared with a chemoimmunotherapy regimen (either fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab).
Adults with previously untreated chronic lymphocytic leukaemia (CLL)
- An additional benefit is not proven.
- The chemoimmunotherapies used in the comparator arm of the AMPLIFY study (fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab) do not correspond to the appropriate comparator therapy defined by the G-BA.
- Consequently, there are no suitable data available for benefit assessment of acalabrutinib in combination with venetoclax and obinutuzumab compared with the appropriate comparator therapy.
Courtesy translation only, please refer to the German original.
Associated procedures
<< List of all resolutions